Reginald L Dean

Summary

Affiliation: Alkermes Inc
Country: USA

Publications

  1. ncbi request reprint The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence
    Reginald L Dean
    Department of Life Sciences, Alkermes, Inc, 88 Sidney Street, Cambridge, MA 02139, USA
    Front Biosci 10:643-55. 2005
  2. doi request reprint Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone
    Reginald L Dean
    Department of Life Sciences and Toxicology, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
    Pharmacol Biochem Behav 89:515-22. 2008
  3. doi request reprint Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats
    Reginald L Dean
    Life Sciences and Toxicology, Alkermes, Inc, Waltham, MA 02451, USA
    Pharmacol Biochem Behav 100:530-7. 2012
  4. doi request reprint Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats
    Mark S Todtenkopf
    Department of Life Sciences and Toxicology, Alkermes, Inc, USA
    Addict Biol 14:408-18. 2009
  5. ncbi request reprint Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats
    Raymond T Bartus
    Alkermes, Inc, Cambridge, MA, USA
    Neuropsychopharmacology 28:1973-82. 2003
  6. doi request reprint Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps
    Raymond T Bartus
    Ceregene, Inc, 9381 Judicial Dr, Suite 130, San Diego, CA 92121, USA
    Psychopharmacology (Berl) 202:15-36. 2009
  7. ncbi request reprint Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions
    Dwaine F Emerich
    Alkermes, Inc, Cambridge, Massachusetts 02139, USA
    Pharm Res 19:1052-60. 2002

Detail Information

Publications7

  1. ncbi request reprint The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence
    Reginald L Dean
    Department of Life Sciences, Alkermes, Inc, 88 Sidney Street, Cambridge, MA 02139, USA
    Front Biosci 10:643-55. 2005
    ..Both naltrexone and the PLG polymer matrix in which it is encapsulated are well tolerated. Clinical trials of Vivitrex are currently ongoing in alcohol dependent patients...
  2. doi request reprint Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone
    Reginald L Dean
    Department of Life Sciences and Toxicology, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
    Pharmacol Biochem Behav 89:515-22. 2008
    ..Thus, opioid receptor blockade with XR-NTX can be overcome in rats with higher doses of opioids without further affecting respiration or locomotor activity...
  3. doi request reprint Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats
    Reginald L Dean
    Life Sciences and Toxicology, Alkermes, Inc, Waltham, MA 02451, USA
    Pharmacol Biochem Behav 100:530-7. 2012
    ..These data suggest an important role for opioid receptors within the GIT in modulating central reward pathways and may provide new insights into strategies for treating reward disorders, including drug dependency...
  4. doi request reprint Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats
    Mark S Todtenkopf
    Department of Life Sciences and Toxicology, Alkermes, Inc, USA
    Addict Biol 14:408-18. 2009
    ..In summary, an extended-release formulation of naltrexone results in significant attenuation of psychostimulant-enhanced BSR that is not observed with acute naltrexone...
  5. ncbi request reprint Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats
    Raymond T Bartus
    Alkermes, Inc, Cambridge, MA, USA
    Neuropsychopharmacology 28:1973-82. 2003
    ..Clinical trials of extended release naltrexone for treating alcohol and opiate dependency are currently ongoing...
  6. doi request reprint Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps
    Raymond T Bartus
    Ceregene, Inc, 9381 Judicial Dr, Suite 130, San Diego, CA 92121, USA
    Psychopharmacology (Berl) 202:15-36. 2009
    ..This effort produced several notable findings that eventually received consensus support, which we have been asked to review...
  7. ncbi request reprint Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions
    Dwaine F Emerich
    Alkermes, Inc, Cambridge, Massachusetts 02139, USA
    Pharm Res 19:1052-60. 2002
    ..The present studies evaluated the ability of injectable, biodegradable microspheres releasing carboplatin, doxorubicin, or 5-fluorouracil to suppress the growth of solid tumors implanted subcutaneously or intramuscularly...